Multinational Biopharmaceutical Company Licenses LabVantage's Sapphire™ To Support Its Core Biomaterial Research for Cancer and Immunological Therapies

LabVantage today announced that a global biopharmaceutical company has licensed LabVantage's Sapphire Laboratory Information Management Suite (LIMS) to automate their research process and establish an enterprise-wide knowledgebase of research data. The global biopharmaceutical company concentrates on the discovery, development and commercialization of groundbreaking therapies designed to treat cancer and immunological diseases. They have successfully marketed a number of commercial products as well as cellular and tissue therapeutics. The division deploying Sapphire is responsible for supplying research expertise to multiple product development teams and pioneered the recovery of stem cells from human placental tissue following the completion of a full-term, successful pregnancy.

Prior to deploying Sapphire, they had to manually intercede to facilitate the efficient entry and routing of work requests for approval. They plan to use Sapphire's automated request approval/rejection routing functionality, along with a number of flexible workflow capabilities, to eliminate the manual intervention and streamline their workflow process, expediting the initiation and execution of their work order requests. Further, they intend to store test results derived from these work requests in Sapphire, providing a central knowledge repository accessible enterprise-wide through a zero footprint web browser.

"We are very excited about this global biopharmaceutical company's decision to deploy Sapphire and we are thrilled with the rapid pace of the project from kick-off to full functionality solution acceptance in less than six months," stated Jim Aurelio, CEO and President of LabVantage, "As the complexity of mission-critical research intensifies, Sapphire continues to support research and discovery organizations with innovative research management solutions that enable them to convert their research into commercialized products and therapeutics."